Who invented the euthanasia machine

If a person makes the decision to commit suicide, is this a better method than others, especially if other methods can traumatize bystanders and rescue workers?

Search for:. Photo via Exit International. I will leave it to my readers to decide — Do you consider it as just a death machine or a technology that allows the right to die at peace. Can Mamata go national? Successful coalitions at the Centre have been usually headed by leaders with weak power bases. Is a green Diwali possible? Ultra right and wrong: Women in India face a new threat to their freedom of choice. Nehru, Iqbal, cricket and the question of Muslim identity.

Hate smug liberals? Interested in blogging for timesofindia. We will be happy to have you on board as a blogger, if you have the knack for writing. Just drop in a mail at toiblogs timesinternet. Accept Reject. Update Consent. Facebook Twitter Linkedin Email. Only when deemed safe in adults and various regulatory bodies have signed off, do the pediatric vaccine trials commence. Because children's immune systems and bodies are in a constant state of development, the vaccines must be right-sized.

Investigators typically conduct "age de-escalation" studies in various age groups. The lowest dose is first tried so see if that is effective, then the dose is increased gradually as needed.

Immune response is the easiest, safest and most efficient way to test the efficacy of pediatric vaccines. This is a typical size and design of a childhood vaccine seeking regulatory approval. There is no reason to think that the clinical efficacy would be any different in children vs.

Although this was primarily designed as an "immunobridging" study, the initial immunologic response data was followed by real clinical outcomes in this population.

Reporting on the outcomes of 2, children in the randomized controlled trial, the vaccine was Myocarditis inflammation of the heart muscle and pericarditis inflammation of the lining of the heart have been associated with receipt of the mRNA vaccines , particularly among male adolescents and young adults, typically within a few days after receiving the second dose. But this is very rare. For every million vaccine recipients, you would expect 41 cases in males, and 4 cases in females aged years-old.

The risk in older age groups is substantially lower. It is important to recognize that the risk of myocarditis associated with COVID is substantially higher. Patients present with new chest pain, shortness of breath, or palpitations after receiving an mRNA vaccine more common after the second dose.

But outcomes are good if associated with the vaccine. Most respond well to treatment and resolve symptoms within a week. There have been no deaths associated with vaccine-associated myocarditis. The risk of myocarditis is likely related to vaccine dose, so the fact that one-third the dose of the vaccine will be used in the year-olds is expected to correspond to a lower risk of myocarditis.

At the lower dose given to younger kids, there has been a lower incidence of adverse effects reported compared to older children and adults who received the full dose.

In addition, baseline rates of myocarditis not associated with vaccination are much lower in children ages years than in older children, so the same may hold true for vaccine-associated myocarditis cases. This is because myocarditis is associated with sex hormones particularly testosterone that surge during puberty.

In support of this, the incidence of vaccine-associated myocarditis is lower in 12—year-old boys , compared to those who were older than 16 years old. There were no cases of myocarditis reported in the experience to date of 5—year-old children in the trials, although the trial was too small to pick up on such a rare effect. There is a biologic basis for increasing the interval between vaccine doses in general. Priming the immune system with the first shot and then waiting gives the second shot a better chance of prompting a secondary immune reaction that results in a more durable response with more T cell driven immune memory.

One study from the U. In a study of British health care workers, there were twice as many neutralizing antibodies produced in a longer interval group weeks versus a shorter interval group weeks between doses. However, the safety and efficacy with longer intervals has not been evaluated in the pediatric or other COVID vaccine trials. In the U. Also, Europe is already experiencing a winter surge of infections that may predict more U.

During a time of high community virus burden with a highly transmissible Delta variant, relying on one dose of vaccine for several more weeks until the second may leave many more susceptible to infection while waiting. There has been no corollary information in children but we would expect less protection in general from one vaccine dose vs.

This is a particularly important issue with the upcoming holiday season when an increased number of families will travel. Some countries such as the U. There are no plans to only offer one vaccine dose in the U. However a lower dose of the vaccine will likely be studied in the future for adolescents aged For parents worried about the potential risk of adverse effects of two doses of vaccines in their children, it is reasonable to wait weeks for the second shot but it all depends on your risk-benefit calculus.

There is biological plausibility to pursue this strategy. Although there is no pediatric-specific data to draw from, a longer interval may lengthen immune memory and potentially decrease the risk of myocarditis, particularly in boys. The inventors put a model of the device on display, together with a set of virtual reality glasses to give visitors a true-to-life experience of what it would be like to sit in the pod, before ultimately pressing the button.

Nitschke said he aimed to build the first fully functioning pod before the end of the year. After that, the design will be put online as an open-source document for people to download.